Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bickham

Showing results (221-230 of 236) with videos related to

Pageof 24
Sort By:
Vaccine|January 9, 2023
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, et al.
Ecotoxicology (London, England)|December 19, 2003
Editorial: the unknown environmental tragedy in Sumgayit, AzerbaijanJohn W Bickham, Cole W Matson, Arif Islamzadeh, et al.
Pediatrics|June 13, 2023
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 StudyNatalie Banniettis, Michael Horn, Manish Sadarangani, et al.
The Pediatric Infectious Disease Journal|July 9, 2020
A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy InfantsHeather L Platt, David Greenberg, Bruce Tapiero, et al.
Cancer Research|October 31, 2012
Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cellsKanako Shimizu, Takuya Mizuno, Jun Shinga, et al.
Vaccine|April 27, 2023
A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, et al.
Vaccine|January 21, 2025
Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398]Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, et al.
Optics Express|February 15, 2012
Mode-division multiplexed transmission with inline few-mode fiber amplifierNeng Bai, Ezra Ip, Yue-Kai Huang, et al.
Nature Ecology & Evolution|July 15, 2021
Author Correction: Determinants of genetic variation across eco-evolutionary scales in pinnipedsClaire R Peart, Sergio Tusso, Saurabh D Pophaly, et al.
Nature Communications|July 1, 2025
An mRNA vaccine encoding five conserved Group A Streptococcus antigensNichaela Harbison-Price, Ismail Sebina, Rhiannon A Bolton, et al.
Pageof 24

Showing results (221-230 of 236) with videos related to

Sort By:
Pageof 24
Vaccine|January 9, 2023
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, et al.
Ecotoxicology (London, England)|December 19, 2003
Editorial: the unknown environmental tragedy in Sumgayit, AzerbaijanJohn W Bickham, Cole W Matson, Arif Islamzadeh, et al.
Pediatrics|June 13, 2023
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 StudyNatalie Banniettis, Michael Horn, Manish Sadarangani, et al.
The Pediatric Infectious Disease Journal|July 9, 2020
A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy InfantsHeather L Platt, David Greenberg, Bruce Tapiero, et al.
Cancer Research|October 31, 2012
Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cellsKanako Shimizu, Takuya Mizuno, Jun Shinga, et al.
Vaccine|April 27, 2023
A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, et al.
Vaccine|January 21, 2025
Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398]Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, et al.
Optics Express|February 15, 2012
Mode-division multiplexed transmission with inline few-mode fiber amplifierNeng Bai, Ezra Ip, Yue-Kai Huang, et al.
Nature Ecology & Evolution|July 15, 2021
Author Correction: Determinants of genetic variation across eco-evolutionary scales in pinnipedsClaire R Peart, Sergio Tusso, Saurabh D Pophaly, et al.
Nature Communications|July 1, 2025
An mRNA vaccine encoding five conserved Group A Streptococcus antigensNichaela Harbison-Price, Ismail Sebina, Rhiannon A Bolton, et al.
Pageof 24